US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Cannabis Concept

240.89

-2.1261-0.87%

Number of Gainers:1

Number of Losers:15

Number of Flat:1

PE:- -

High:246.55

Open:243.00

Low:239.56

Close:243.01

Volume:16.95M

Turnover:171.74M

Market Cap:58.10B

Float Cap:52.31B

Loading ...

Asian Equities Traded in the US as American Depositary Receipts Start Week Slightly Higher in Monday Trading

MT Newswires Live

AIM announces planned milestones in Phase 2 trial of Ampligen, Durvalumab

AIM ImmunoTech Inc. Makes Updated Corporate Presentation Available

FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application

Harrow (HROW) Valuation Check As PharmaPack Launch Targets Cataract Surgery Market

Simply Wall St.

Aurora UK Alpha Affirms MAR Compliance and Trading Ability in Closed Period

Nelson Resources Relocates Registered Office to Perth CBD

Teva Pharmaceutical Says FDA Accepts New Drug Application for Olanzapine in Schizophrenia Treatment

MT Newswires Live

FDA accepts Teva NDA for olanzapine extended-release injectable suspension

Dr. Reddy's Secures FDA Review for Abatacept Biologics License Application

MT Newswires Live

Aurora Innovation Years Ahead of Competitors, Oppenheimer Says

MT Newswires Live

Press Release: Green Thumb Industries Announces an Additional $50 Million Senior Debt Financing

Amphastar Pharmaceuticals Inc. published an update to their financial calendar

Hargreave Hale AIM VCT Expands Share Capital with New LSE Admissions

SNDL Sets March 12 Release Date for Q4 and Full-Year 2025 Results

BRIEF-Corcept Says US Court Rules Teva's Generic Korlym Does Not Infringe Corcept Patents

SNDL Inc. Publishes Financial Calendar Update

Corcept Therapeutics Inc - Ruling Affirms December 2023 Verdict by Federal District Court

THOMSON REUTERS

Corcept Therapeutics Inc - Considering Judicial Review of Court Decision

THOMSON REUTERS

Corcept Provides Update on Patent Dispute With Teva Pharmaceuticals

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4557/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4557","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4557\",,,,,undefined,":{"symbol":"BK4557","market":"US","secType":"PLATE","nameCN":"Cannabis Concept","latestPrice":240.88689,"timestamp":1771876693080,"preClose":243.013,"halted":0,"volume":16951543,"delay":0,"changeRate":-0.008749,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-2.126114,"latestTime":"02-23 14:58:13 EST","open":243.00298,"high":246.54514,"low":239.56474,"amount":171740731.276509,"amplitude":0.028724,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771880400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.296125,"peRate":-148.01318,"turnoverRate":0.005805,"increases":1,"decrements":15,"flats":0,"marketCap":58104326215.5,"floatMarketCap":52311438294.75},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4557\",,,,,undefined,":{"symbol":"BK4557","high":246.54514,"amplitude":0.028724,"preClose":243.013,"low":239.56474,"pbRate":"3.296125","latestPrice":240.88689,"volume":16951543,"delay":0,"open":243.00298,"prevYearClose":226.48174,"prevWeekClose":243.013,"prevMonthClose":237.0625,"prevQuarterClose":226.4817,"fiveDayClose":239.5535,"twentyDayClose":228.1016,"sixtyDayClose":163.0901,"secType":"PLATE","market":"US","turnoverRate":0.005805,"peRate":-148.01318,"marketCap":58104326215.5,"floatMarketCap":52311438294.75,"timestamp":1771876693080,"nameCN":"Cannabis Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4557\",,,,undefined,":{"bkCode":"BK4557","up":1,"down":15,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4557\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613733343","title":"Asian Equities Traded in the US as American Depositary Receipts Start Week Slightly Higher in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2613733343","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613733343?lang=en_us&edition=fundamental","pubTime":"2026-02-23 23:35","pubTimestamp":1771860957,"startTime":"0","endTime":"0","summary":"Asian equities traded in the US as American depositary receipts opened the week modestly higher Monday morning, rising 0.10% to 2,989.81 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by electric vehicle maker NIO  and thin-film liquid display maker LG Display , which advanced 5.7% and 3.6%, respectively. They were followed by online game developer The9  and healthcare platform 111 , which increased 3.5% and 2.7,% respectively.The decliners from North Asia were led by automotive marketplace Cango  and computer hardware Canaan , which dropped 7% and 5.5,% respectively. They were followed by fintech firm Jiayin Group  and travel company Tuniu , which lost 2.7% and 1.6% respectively.From South Asia, the gainers were led by telecommunications operators Telekomunikasi Indonesia  and PLDT , which rose 1.6% each. They were followed by pharmaceutical company Dr. Reddy's Laboratories  and lender HDFC Bank , which were up 1.2% and 0.7%, respectively.The decliners from South A","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4509","LU0918141705.HKD","LU1861220207.SGD","BK4505","LU0348816934.USD","LU0918141887.USD","BK4523","LU0979878070.USD","LU0868486357.SGD","LU1323998911.USD","LU0791590937.USD","NCTY","LU0516422366.SGD","CAN","NIO.SI","LU0823039010.USD","LU0289960550.SGD","LU0516422440.USD","BK7508","LU0541501648.USD","BK4132","LU2045819591.USD","BK4128","LU1805238398.USD","LU0197773160.USD","BK4526","LU0251143029.SGD","BK4122","IE00B3M56506.USD","SG9999014039.USD","LU0589944569.HKD","LU0572939691.SGD","BK4535","TOUR","SG9999013478.USD","BK4220","LU2065171311.SGD","LU0348788117.USD","BK4134","LU1854103824.USD","BK4574","LU2087589342.USD","BK4595","BK7096","BK4518","BK4207","LU0066902890.USD","LU0210637038.USD","IE0001KFT4U8.USD","BK4503","IE0034224299.USD","LU2125910849.SGD","BK4581","LU0231203729.USD","JFIN","LU2065170008.USD","LU0862451753.SGD","LU0898667661.SGD","TLK","LU1839390173.USD","BK4115","BK4214","HDB","LU1242518931.SGD","LU1366334578.USD","LU0541502299.USD","PHI","LU0797268264.HKD","BK4533","LU0572940350.SGD","LU0791591158.USD","SG9999014484.SGD","LU0052750758.USD","BK4142","LU0345776255.USD","LU0456842615.SGD","RDY","09866","LU0264606111.USD","LU1861217088.USD","SG9999013460.SGD","LU0164881194.USD","BK4085","WIT","LU1508157978.USD","LU2152927971.USD","IE00BYTNYM70.SGD","LU0175139822.USD","BK4170","BK4588","BK7016","LU0630378429.USD","LU0708995666.HKD","LU1804176565.USD","LU2543165471.USD","YI","IE00BD6J9T35.USD","BK4532","LU2125910500.SGD","BK4148","LU0499858438.USD","SG9999014005.SGD","LU2065169927.USD","BK4117","LU2265009873.SGD","LU0348814723.USD","BK4548","LU0531971678.HKD","SG9999002414.USD","LU0528227936.USD","LU0441851309.USD","LU1105468828.SGD","LU0072462343.USD","LU0307460401.USD","LU0516422952.EUR","LU1791710582.SGD","LU2238330802.EUR","INFY","BK4596","LU0737861269.HKD","SG9999001135.SGD","BK4585","BK4504","LU1242518857.USD","SG9999002406.SGD","IE0031814969.USD","SG9999002620.SGD","LU0532188223.SGD","BK4600","LU1366334651.USD","LU2008162690.USD","LU0536402901.SGD","SG9999004360.SGD","BK4577","BK4534","LU0630378692.HKD","LU0516423091.SGD","LU1048588211.SGD","IE00B7N09G41.SGD","LU2279701549.SGD","LU2226246903.HKD","LU0197229882.USD","LU0708995583.HKD","BK4023","SG9999014492.USD","LU0345775950.USD","LU2663582299.SGD","SIFY","CANG","LU0823038988.USD","BK4107","NIOG","BK4555","BK4531","SG9999005177.SGD","LU0431992006.USD","BK4557","SG9999006266.SGD","SG9999014013.SGD","LU0499858602.USD","NIO","BK4099","BK4007","LU0261945553.USD","SG9999014021.USD","LU1854104046.USD","LU0333810181.USD","BK7502","SGXZ58947870.SGD","SG9999002679.SGD","LU0320764599.SGD","LU0287143357.SGD","LU0890818403.SGD","BK4554","LU1267930656.SGD","LU0390134368.USD","EVS.SI","LU2065171402.SGD","BK4166","LU0831103253.SGD","LU2177674079.SGD","LU0048573645.USD","LU0197773673.USD","SE","SG9999002604.SGD","SG9999013486.USD","BK4566","LU0348744763.USD","BK4089","BK4551","LU1770036033.HKD","LU1791710400.SGD","LU2360107671.USD","LU0516423174.USD","IE00B0JY6M65.USD","LU1102505762.USD","LPL","LU1282648689.USD"],"gpt_icon":1},{"id":"2613780616","title":"AIM announces planned milestones in Phase 2 trial of Ampligen, Durvalumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2613780616","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613780616?lang=en_us&edition=fundamental","pubTime":"2026-02-23 22:07","pubTimestamp":1771855625,"startTime":"0","endTime":"0","summary":"AIM ImmunoTech (AIM) announced milestones in the expected timeline for the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen combined w...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aim-announces-planned-milestones-in-phase-2-trial-of-ampligen-durvalumab-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aim-announces-planned-milestones-in-phase-2-trial-of-ampligen-durvalumab-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AIM","BK4557"],"gpt_icon":0},{"id":"2613787920","title":"AIM ImmunoTech Inc. Makes Updated Corporate Presentation Available","url":"https://stock-news.laohu8.com/highlight/detail?id=2613787920","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613787920?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:55","pubTimestamp":1771854918,"startTime":"0","endTime":"0","summary":"AIM ImmunoTech Inc. said it has published an updated corporate presentation on its website titled “Ampligen Breakthroughs in Treating Late-Stage Pancreatic Cancer: Corporate Presentation - February 2026.” The document is available at Ampligen Breakthroughs in Treating Late-Stage Pancreatic Cancer: Corporate Presentation - February 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire  on February 23, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL59wf4m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","NDAQ","LU2210149790.SGD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4588","AIM","SG9999014021.USD","LU2095319765.USD","SG9999014039.USD","BK4557","IE00B64PRP62.GBP","SG9999014005.SGD","BK4139","SG9999014013.SGD","IE00BKPKM429.USD","LU2210150020.SGD","BK4585","BK4112"],"gpt_icon":0},{"id":"2613480787","title":"FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2613480787","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613480787?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:48","pubTimestamp":1771854480,"startTime":"0","endTime":"0","summary":"Teva Pharmaceuticals Industries Ltd  on Friday announced that the U.S. Food and Drug Administration  has accepted its New Drug Application  for olanzapine extended-release injectable suspension.The marketing application for TEV-‘749 is based on results from the Phase 3 SOLARIS trial, which demonstrated an efficacy and safety profile consistent with currently available olanzapine formulations.This investigational drug aims to improve treatment adherence for individuals living with schizophrenia, addressing a critical gap in care.In the SOLARIS trial, TEV-‘749 was administered as a once-monthly subcutaneous injection, showing no evidence for the need for post-injection monitoring, which is typically required for other formulations.The acceptance of this NDA marks a significant milestone for Teva as it seeks to provide a long-acting option for patients who rely on olanzapine.TEV-‘749 utilizes SteadyTeq, a copolymer technology proprietary to Medincell that provides a controlled, steady, su","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/23/Brain-to-Heart-Growth.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/23/Brain-to-Heart-Growth.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/fda/26/02/50777798/fda-accepts-tevas-new-long-acting-schizophrenia-treatment-application","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/26/02/50777798/fda-accepts-tevas-new-long-acting-schizophrenia-treatment-application","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4584","TEVA","BK4596","BK4566","BK4588","BK4007","LU1983299246.USD","BK4585","BK4217","BK4559","BK4557","LU2324357040.USD","SMA"],"gpt_icon":0},{"id":"2613978903","title":"Harrow (HROW) Valuation Check As PharmaPack Launch Targets Cataract Surgery Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2613978903","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613978903?lang=en_us&edition=fundamental","pubTime":"2026-02-23 19:30","pubTimestamp":1771846210,"startTime":"0","endTime":"0","summary":"PharmaPack launch puts Harrow stock in focus\nHarrow (HROW) has drawn fresh attention after launching PharmaPack, a direct-to-prescriber cash-pay program offering FDA-approved ophthalmic kits intended to replace off-label compounded products used around cataract surgery.\nSee our latest analysis for Harrow.\nThe PharmaPack announcement comes as Harrow’s short term share price momentum is strong, with a 1 month share price return of 16.93% and a 90 day share price return of 26.77%, set against a...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrow/harrow/news/harrow-hrow-valuation-check-as-pharmapack-launch-targets-cat","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-hrow/harrow/news/harrow-hrow-valuation-check-as-pharmapack-launch-targets-cat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4557","HROW","BK4007"],"gpt_icon":0},{"id":"2613100788","title":"Aurora UK Alpha Affirms MAR Compliance and Trading Ability in Closed Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2613100788","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613100788?lang=en_us&edition=fundamental","pubTime":"2026-02-23 17:17","pubTimestamp":1771838243,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Aurora Investment Trust PLC ( ($GB:ARR) ). Aurora UK Alpha plc has confirmed its compliance with Market Abuse R...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aurora-uk-alpha-affirms-mar-compliance-and-trading-ability-in-closed-period?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aurora-uk-alpha-affirms-mar-compliance-and-trading-ability-in-closed-period?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GB00B4LPDJ14.GBP","BK4588","BK4557","IE00B95QR487.USD","ACB","IE00B1G9WX41.USD","ABIL","IE00B45NX917.SGD","LU0690374961.EUR","BK4142","LU2404859667.USD","LU1718418525.SGD","LU0690374615.EUR","BK4585","LU2404859741.USD","MAR","MSOS","IE00BD0PCF45.HKD","BK4007","IE00B0T0GQ85.USD","GB00B4QBRK32.GBP"],"gpt_icon":0},{"id":"2613207683","title":"Nelson Resources Relocates Registered Office to Perth CBD","url":"https://stock-news.laohu8.com/highlight/detail?id=2613207683","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613207683?lang=en_us&edition=fundamental","pubTime":"2026-02-23 15:59","pubTimestamp":1771833547,"startTime":"0","endTime":"0","summary":"Nelson Resources Ltd. ( ($AU:NES) ) has issued an announcement. Nelson Resources Limited has announced a change to its registered and principal pla...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nelson-resources-relocates-registered-office-to-perth-cbd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nelson-resources-relocates-registered-office-to-perth-cbd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4557","MSOS","CBD","BK4113","ACB"],"gpt_icon":0},{"id":"2613829408","title":"Teva Pharmaceutical Says FDA Accepts New Drug Application for Olanzapine in Schizophrenia Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2613829408","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613829408?lang=en_us&edition=fundamental","pubTime":"2026-02-21 04:05","pubTimestamp":1771617940,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries  said Friday that the US Food and Drug Administration has accepted the company's New Drug Application for olanzapine extended-release injectable suspension, or TEV-'749, for the treatment of schizophrenia in adults.The application for TEV-'749 is based on results from the phase 3 Solaris trial that demonstrated an efficacy and safety profile consistent with other available olanzapine formulations, and showed no evidence for the need for post-injection monitoring, Teva Pharmaceutical Industries said.Shares of the company were down over 1% in recent Friday trading.Price: 34.00, Change: -0.33, Percent Change: -0.96","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LU2324357040.USD","BK4584","BK4596","BK4585","BK4557","BK4588","BK4559","LU1983299246.USD","TEVA","BK4566"],"gpt_icon":0},{"id":"2613129475","title":"FDA accepts Teva NDA for olanzapine extended-release injectable suspension","url":"https://stock-news.laohu8.com/highlight/detail?id=2613129475","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613129475?lang=en_us&edition=fundamental","pubTime":"2026-02-21 03:55","pubTimestamp":1771617319,"startTime":"0","endTime":"0","summary":"Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and Medincell announced that the U.S. Food and Drug Administr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fda-accepts-teva-nda-for-olanzapine-extended-release-injectable-suspension-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fda-accepts-teva-nda-for-olanzapine-extended-release-injectable-suspension-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4596","BK4566","BK4557","BK4588","BK4585","TEVA","LU2324357040.USD","BK4559","BK4007","LU1983299246.USD","BK4584"],"gpt_icon":0},{"id":"2613295236","title":"Dr. Reddy's Secures FDA Review for Abatacept Biologics License Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2613295236","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613295236?lang=en_us&edition=fundamental","pubTime":"2026-02-21 00:29","pubTimestamp":1771604952,"startTime":"0","endTime":"0","summary":"Dr. Reddy's Laboratories (RDY) said Friday the US Food and Drug Administration has accepted for review its biologics license application for an IV infusion formulation of DRL_AB, a proposed biosimilar","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7016","LU0348744763.USD","BK4596","RDY.AU","BK4532","RDY","BK4557","BK4523","BK4007"],"gpt_icon":0},{"id":"2612416298","title":"Aurora Innovation Years Ahead of Competitors, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2612416298","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612416298?lang=en_us&edition=fundamental","pubTime":"2026-02-20 23:06","pubTimestamp":1771600001,"startTime":"0","endTime":"0","summary":"Aurora Innovation  is years ahead of is competitors in creating fully self-driving on-road commercial vehicles, Oppenheimer analysts said in a note to clients Friday.\"We are encouraged by the efficiency of its technology foundation, which is enabling rapid Operating Design Domain expansion leveraging on-road experience and simulation capabilities,\" the analysts wrote.Oppenheimer said demand for the company's vehicles remains strong, and exceeds its planned production schedule. It also estimates savings of approximately 15% of driver expense, and fuel savings of 14% to 34%.\"It appears that AUR's unit economics would put non-automated carriers at a significant disadvantage which should further drive adoption,\" the analysts wrote.Price: 4.82, Change: -0.04, Percent Change: -0.93","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AUR","BK4137","AUR.AU","BK7095","OPY","MSOS","ACB","BK4023","BK4557","BK4007","BK4127"],"gpt_icon":0},{"id":"2612261954","title":"Press Release: Green Thumb Industries Announces an Additional $50 Million Senior Debt Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2612261954","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612261954?lang=en_us&edition=fundamental","pubTime":"2026-02-20 20:00","pubTimestamp":1771588800,"startTime":"0","endTime":"0","summary":"CHICAGO and VANCOUVER, British Columbia, Feb. 20, 2026  -- Green Thumb Industries Inc.   , a leading national cannabis consumer packaged goods company and owner of RISE Dispensaries, today announced the Company increased its existing syndicated credit facility led by Valley National Bank by $50 million, bringing the total facility to $189 million. The Company intends to use the cash proceeds for general corporate purposes, potential strategic investments, and other working capital requirements.\"Adding $50 million to our balance sheet at a low rate should be good for our shareholders long term,\" said Founder, Chairman and Chief Executive Officer Ben Kovler. \"We are fortunate to have Valley National Bank as a financing partner who has confidence in our business model and capital stewardship.\". The credit facility has a maturity date of September 11, 2029 and will continue to bear interest from the date of issue at Secured Overnight Financing Rate  + 500 basis points. This transaction did","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GTBIF","BK4557","SOFR"],"gpt_icon":0},{"id":"2612266926","title":"Amphastar Pharmaceuticals Inc. published an update to their financial calendar","url":"https://stock-news.laohu8.com/highlight/detail?id=2612266926","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612266926?lang=en_us&edition=fundamental","pubTime":"2026-02-20 19:00","pubTimestamp":1771585216,"startTime":"0","endTime":"0","summary":"- **Q4 2025 earnings release:** Amphastar Pharmaceuticals, Inc. will release its fourth-quarter earnings results on **Thursday, February 26, 2026**, **after the market closes**. Results will be available on the Investors page at www.amphastar.com. - **Earnings conference call:** Amphastar will hold a conference call to discuss the results on **February 26, 2026 at 2:00 p.m. Pacific Time**, accessible via the Investors page at www.amphastar.com. **Bill Peters ** is listed as the contact.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL8ZCyLn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","BK4585","BK4007","BK4588","AMPH"],"gpt_icon":0},{"id":"2612266173","title":"Hargreave Hale AIM VCT Expands Share Capital with New LSE Admissions","url":"https://stock-news.laohu8.com/highlight/detail?id=2612266173","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612266173?lang=en_us&edition=fundamental","pubTime":"2026-02-20 18:43","pubTimestamp":1771584229,"startTime":"0","endTime":"0","summary":"Hargreave Hale AIM VCT 1 ( ($GB:HHV) ) has issued an announcement. Hargreave Hale AIM VCT PLC has increased its issued share capital through the ad...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/hargreave-hale-aim-vct-expands-share-capital-with-new-lse-admissions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/hargreave-hale-aim-vct-expands-share-capital-with-new-lse-admissions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4179","LSE","BK4557","AIM"],"gpt_icon":0},{"id":"2612239872","title":"SNDL Sets March 12 Release Date for Q4 and Full-Year 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2612239872","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612239872?lang=en_us&edition=fundamental","pubTime":"2026-02-20 06:08","pubTimestamp":1771538932,"startTime":"0","endTime":"0","summary":"An announcement from SNDL ( ($SNDL) ) is now available. On February 19, 2026, SNDL Inc. said it will publish its fourth quarter and full-year 2025 ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sndl-sets-march-12-release-date-for-q4-and-full-year-2025-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sndl-sets-march-12-release-date-for-q4-and-full-year-2025-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4547","BK4557","BK4007","SNDL"],"gpt_icon":0},{"id":"2612929235","title":"BRIEF-Corcept Says US Court Rules Teva's Generic Korlym Does Not Infringe Corcept Patents","url":"https://stock-news.laohu8.com/highlight/detail?id=2612929235","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612929235?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:35","pubTimestamp":1771536943,"startTime":"0","endTime":"0","summary":"BRIEF-Corcept Says US Court Rules Teva's Generic Korlym Does Not Infringe Corcept PatentsFeb 19 (Reuters) - Corcept Therapeutics Inc CORT.O:CORCEPT PROVIDES UPDATE ON PATENT DISPUTE WITH TEVA PHARMACE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUABQN0YZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1983299246.USD","LU2324357040.USD","BK4585","TEVA","BK4584","BK4566","BK4596","LU1559883803.SGD","BK4007","BK4588","BK4532","BK4557","CORT","LU0566484027.USD","BK4559"],"gpt_icon":0},{"id":"2612235342","title":"SNDL Inc. Publishes Financial Calendar Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2612235342","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612235342?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:31","pubTimestamp":1771536667,"startTime":"0","endTime":"0","summary":"SNDL Inc. Publishes Financial Calendar Update               SNDL Inc. will release its fourth quarter 2025 and full year 2025 financial results before markets open on March 12, 2026. SNDL will host a ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDLblDtj3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDL","BK4588","LU2210149790.SGD","BK4585","LU2095319765.USD","LU2210150020.SGD","SG9999014005.SGD","SG9999014021.USD","NDAQ","LU0314104364.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014039.USD","IE00BGHQF748.EUR","BK4557","SG9999014013.SGD","BK4007","IE00B3QW5Z07.USD","BK4112","BK4547"],"gpt_icon":0},{"id":"2612728001","title":"Corcept Therapeutics Inc - Ruling Affirms December 2023 Verdict by Federal District Court","url":"https://stock-news.laohu8.com/highlight/detail?id=2612728001","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612728001?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:00","pubTimestamp":1771534800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUABQN0YZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4557","BK4007","LU0566484027.USD","LU1983299246.USD","LU2324357040.USD","BK4532","TEVA","BK4559","LU1559883803.SGD","BK4585","BK4596","BK4584","BK4588","BK4566","CORT"],"gpt_icon":0},{"id":"2612280046","title":"Corcept Therapeutics Inc - Considering Judicial Review of Court Decision","url":"https://stock-news.laohu8.com/highlight/detail?id=2612280046","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612280046?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:00","pubTimestamp":1771534800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUABQN0YZ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1559883803.SGD","BK4588","BK4532","BK4584","BK4557","LU0566484027.USD","LU2324357040.USD","CORT","LU1983299246.USD","BK4559","TEVA","BK4596","BK4585","BK4566","BK4007"],"gpt_icon":0},{"id":"2612044280","title":"Corcept Provides Update on Patent Dispute With Teva Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2612044280","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612044280?lang=en_us&edition=fundamental","pubTime":"2026-02-20 05:00","pubTimestamp":1771534800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUABQN0YZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TEVA","BK4532","CORT","LU1983299246.USD","BK4584","BK4588","BK4596","BK4559","LU2324357040.USD","LU0566484027.USD","BK4566","LU1559883803.SGD","BK4557","BK4007","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":100,"code":"91000000","status":"200"}]}}